Suzanne Jung Angell

Board Member

Suzanne Jung Angell is Director of Therapeutic Research at Casdin Capital, a New York-based research investment firm focused on the innovations in molecular medicine currently reshaping Life Sciences and healthcare. Suzanne is a board observer for numerous portfolio companies, including Leyden Labs. Suzanne began her investing career in 1999 at Cooper Hill Partners. Over her career, she has invested in and partnered with companies in biotechnology, life science tools, diagnostics, and medical devices. With her own experience as a manager and operator in diverse businesses, Suzanne has a keen appreciation for the challenges facing entrepreneurs as they grow their businesses. Suzanne has a B.A. in Biology and English from Yale University and an M.A. in English Literature from Johns Hopkins University.